Rethinking oncology launches: How the next generation of patients is reshaping strategies

Oncology care is undergoing a seismic shift, with an increase in younger patients facing cancer diagnoses. Between 1990 and 2019, there was an alarming 79% increase in cancer cases globally for patients under 50 years old, particularly in colorectal, breast, and pancreatic cancers.1 In early-onset diagnoses, this demographic expects a reimagined approach to patient support, and biopharma manufacturers need to adapt their drug development and commercialization strategies. To navigate this paradigm shift, they must address the unique needs of younger patients to drive meaningful innovation across the oncology care continuum.